NASDAQ ยท Dividend

Royalty Pharma plc (RPRX) Dividend

$63.86 NASDAQ: RPRX Market Cap $28.44B
MetricValue
Dividend Yield1.61%
Indicated Annual Dividend$1.03
Payout Ratioโ€”
FCF Yieldโ€”
Current Price$63.86

Dividend Analysis

Royalty Pharma plc (RPRX) currently pays a dividend yielding 1.61%, an indicated annual rate of roughly $1.03 per share.

The payout ratio is 0.0% of earnings; free cash flow yield of 0.00% is below the 1.61% dividend yield, so the dividend is not fully covered by free cash flow at the current price.

Payment schedule

MeasureValue
Indicated annual dividendYield times the current share price.$1.03
Dividend yieldAnnual dividend as a percentage of the share price.1.61%

Dividend income by amount invested

At today's price and the current indicated dividend. Shares are not rounded to whole numbers, and a future dividend is never guaranteed.

InvestedSharesIncome per year
$1,00015.7$16.10
$5,00078.3$80.50
$10,000156.6$161.00
$25,000391.5$402.50
$50,000783.0$805.00

Yield across the 52-week range

Yield moves opposite the share price. Holding the current dividend constant, this is what the yield would have been at each end of the last year's range.

Share pricePriceYield
At the 52-week high$64.381.60%
Today$63.861.61%
At the 52-week low$35.232.92%

Royalty Pharma plc (RPRX) dividend โ€” frequently asked questions

Does Royalty Pharma plc (RPRX) pay a dividend?

Yes. Royalty Pharma plc (RPRX) pays a dividend yielding 1.61%, an indicated annual rate of about $1.03 per share.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
RPRX Overview RPRX Financials Screen Dividend Stocks

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.